Last 48 quarters of trend data · Healthcare · Drug Manufacturers - Specialty & Generic
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -236.21 | — | — | 68.06 | 459.73 | 58.73 | — | 44.14 | — | — | — | — | — | — | — | 103.07 | — | — | — | — | — |
| — | — | — | +54.2% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 4.53 | 5.61 | 7.42 | 5.05 | 6.54 | 4.65 | 4.98 | 4.49 | 8.15 | 3.80 | 3.39 | 2.72 | 3.59 | 4.33 | 6.14 | 5.34 | 3.62 | 2.13 | 2.10 | 2.94 | 3.29 |
| — | +20.6% | +49.1% | +12.5% | -19.8% | +22.4% | +46.8% | +65.0% | +126.8% | -12.3% | -44.7% | -49.0% | -0.7% | +103.3% | +192.5% | +81.7% | +9.8% | -37.8% | -30.1% | -2.8% | +25.2% | |
| P/B Ratio | 23.34 | 106.86 | 46.30 | 34.58 | 40.14 | 24.07 | 16.99 | 17.34 | 27.86 | 12.79 | 7.79 | 5.66 | 6.53 | 26.30 | 29.77 | 15.95 | 382.97 | 36.85 | 19.07 | 21.72 | 15.18 |
| — | +343.9% | +172.6% | +99.5% | +44.1% | +88.2% | +118.0% | +206.5% | +326.7% | -51.4% | -73.8% | -64.5% | -98.3% | -28.6% | +56.1% | -26.6% | +2422.6% | +239.0% | +186.6% | +229.8% | +149.9% | |
| P/FCF | 28.83 | — | — | 55.80 | 28.62 | — | 12.25 | — | 170.98 | — | — | 11.66 | — | 43.71 | — | — | — | 10.80 | 82.45 | — | — |
| — | — | — | — | -83.3% | — | — | — | — | — | — | — | — | +304.6% | — | — | — | -25.4% | +430.6% | — | — | |
| EV / EBITDA | 24.55 | — | — | 17.18 | 26.54 | 21.35 | — | 19.99 | 101.04 | 49.40 | — | — | 33.37 | 33.87 | 54.81 | — | 192.43 | 23.56 | 19.34 | — | — |
| — | — | — | -14.1% | -73.7% | -56.8% | — | — | +202.8% | +45.9% | — | — | -82.7% | +43.7% | +183.4% | — | — | +70.7% | +31.3% | — | — | |
| EV / EBIT | 36.56 | — | — | 31.77 | 72.63 | 29.92 | — | 26.29 | 326.16 | — | — | — | 88.35 | 78.08 | 164.96 | — | — | 34.42 | 26.52 | — | — |
| — | — | — | +20.9% | -77.7% | — | — | — | +269.2% | — | — | — | — | +126.8% | +522.0% | — | — | +127.6% | +54.7% | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 75.1% | 71.3% | 61.2% | 79.3% | 75.3% | 74.5% | 67.5% | 78.8% | 75.6% | 74.4% | 69.5% | 68.9% | 70.6% | 70.1% | 68.3% | 69.7% | 70.6% | 72.0% | 73.0% | 74.8% | 73.6% |
| — | -4.4% | -9.4% | +0.5% | -0.4% | +0.2% | -2.8% | +14.4% | +7.1% | +6.1% | +1.7% | -1.1% | +0.1% | -2.6% | -6.5% | -6.9% | -4.1% | -4.8% | -3.4% | +2.5% | -1.0% | |
| Operating Margin | 14.2% | -15.6% | -50.0% | 27.0% | 20.6% | 17.9% | -23.5% | 19.3% | 2.7% | 3.1% | -20.0% | -13.4% | 5.1% | 7.0% | 4.6% | -8.7% | -0.4% | 7.2% | 9.5% | -8.7% | -19.9% |
| — | -187.0% | -112.7% | +39.8% | +667.6% | +472.5% | -17.2% | +243.9% | -47.3% | -55.5% | -532.1% | -53.3% | +1335.7% | -3.0% | -51.2% | -0.6% | +97.9% | -68.5% | -49.7% | -148.3% | -279.1% | |
| Net Margin | -1.9% | -24.4% | -62.4% | 7.4% | 1.4% | 7.8% | -37.2% | 10.1% | -8.6% | -13.2% | -39.2% | -25.2% | -12.8% | -12.6% | -25.4% | 5.2% | -28.3% | -26.8% | -11.0% | -36.7% | -44.5% |
| — | -411.9% | -68.0% | -26.7% | +116.6% | +159.2% | +5.2% | +140.3% | +33.1% | -4.7% | -54.1% | -584.9% | +54.8% | +52.8% | -130.9% | +114.1% | +36.4% | -95.8% | -884.4% | -566.7% | -174.2% |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -8.5% | -80.0% | -68.6% | 13.4% | 2.1% | 9.5% | -28.4% | 10.7% | -7.3% | -10.9% | -20.8% | -12.6% | -9.0% | -19.4% | -27.2% | 7.5% | -206.6% | -82.5% | -23.6% | -54.6% | -42.6% |
| — | -943.6% | -142.0% | +25.7% | +129.2% | +186.7% | -36.1% | +184.9% | +19.1% | +43.7% | +23.5% | -267.6% | +95.6% | +76.5% | -15.5% | +113.7% | -384.9% | -744.0% | -3073.7% | -1330.0% | -199.5% | |
| ROA | -1.3% | -4.1% | -6.7% | 1.7% | 0.3% | 1.4% | -4.7% | 1.8% | -1.3% | -2.1% | -4.5% | -3.1% | -1.7% | -1.9% | -3.5% | 0.8% | -6.6% | -6.4% | -2.5% | -7.4% | -7.9% |
| — | -393.2% | -42.8% | -5.1% | +122.5% | +165.5% | -5.7% | +159.8% | +25.5% | -12.2% | -26.1% | -471.9% | +73.8% | +70.0% | -42.4% | +111.2% | +17.4% | -110.0% | -752.2% | -475.4% | -150.1% | |
| ROIC | 12.0% | -3.5% | -7.1% | 7.9% | 4.9% | 3.8% | -3.6% | 4.5% | 0.5% | 0.6% | -2.8% | -1.9% | 0.7% | 1.0% | 0.8% | -3.4% | -0.2% | 2.9% | 3.4% | -3.2% | -9.0% |
| — | -192.5% | -98.6% | +76.8% | +791.0% | +505.3% | -27.5% | +336.4% | -21.0% | -36.2% | -444.1% | +43.5% | +473.3% | -66.3% | -75.7% | -4.1% | +97.9% | -67.6% | -31.9% | -173.5% | -399.6% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 4.84 | 20.26 | 10.61 | 4.84 | 5.40 | 4.69 | 4.10 | 3.30 | 3.40 | 3.31 | 3.18 | 2.72 | 2.52 | 8.05 | 8.21 | 4.12 | 93.34 | 14.90 | 8.13 | 7.13 | 4.71 |
| — | +331.9% | +158.6% | +46.5% | +58.6% | +41.9% | +28.8% | +21.3% | +35.2% | -58.9% | -61.2% | -33.9% | -97.3% | -46.0% | +1.0% | -42.2% | +1881.2% | +345.3% | +990.5% | +713.0% | +383.4% | |
| Debt / EBITDA | 4.38 | — | — | 8.74 | 13.04 | 14.47 | — | 13.23 | 45.84 | 43.91 | — | — | 41.08 | 32.72 | 48.53 | — | 169.39 | 32.56 | 27.47 | — | — |
| — | — | — | -33.9% | -71.6% | -67.0% | — | — | +11.6% | +34.2% | — | — | -75.7% | +0.5% | +76.7% | — | — | +94.5% | +348.6% | — | — | |
| Current Ratio | 2.20 | 2.24 | 2.48 | 2.20 | 2.72 | 0.62 | 0.91 | 2.08 | 1.55 | 2.60 | 3.00 | 2.82 | 5.80 | 2.62 | 2.92 | 6.35 | 3.49 | 5.01 | 6.79 | 6.24 | 8.70 |
| — | +260.6% | +173.1% | +5.9% | +75.4% | -76.1% | -69.8% | -26.3% | -73.3% | -0.7% | +2.9% | -55.6% | +66.2% | -47.7% | -57.0% | +1.7% | -59.9% | -56.4% | +68.2% | +64.4% | +192.5% | |
| Quick Ratio | 2.06 | 2.08 | 2.30 | 2.06 | 2.52 | 0.58 | 0.85 | 1.96 | 1.44 | 2.43 | 2.75 | 2.60 | 5.33 | 2.25 | 2.41 | 6.00 | 3.20 | 4.61 | 6.31 | 5.81 | 8.32 |
| — | +261.0% | +170.2% | +5.1% | +74.8% | -76.3% | -69.1% | -24.6% | -72.9% | +7.9% | +14.2% | -56.7% | +66.4% | -51.2% | -61.9% | +3.3% | -61.6% | -58.1% | +75.8% | +69.4% | +210.0% | |
| Interest Coverage | 0.93 | -1.76 | -4.02 | 3.00 | 1.17 | 1.78 | -1.72 | 2.06 | 0.24 | -0.06 | -1.51 | -0.88 | 0.30 | 0.41 | 0.25 | -0.96 | -0.05 | 0.94 | 1.17 | -0.00 | -2.21 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 48 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying HROW stock.
Harrow Health, Inc.'s current P/E is -236.2x. The average P/E over the last 2 quarters is 263.9x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Harrow Health, Inc.'s current operating margin is 14.2%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Harrow Health, Inc.'s business trajectory between earnings reports.